Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFORM-SVR interferon-free danoprevir + RO5024048 ± ribavirin in chronic hepatitis C
2010-022067-35Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of mericitabine, danoprevir, ritonavir, ribavirin and peginterferon alfa-2a in hepatitis C virus infection and chronic hepatitis C (CHC) (3 arms), sponsored by Roche. Primary endpoint: Sustained virological response at 24 weeks post-treatment (SVR24). Started Nov 2010; status: completed.
02
Drugs
mericitabinedanoprevirritonavirribavirinpeginterferon alfa-2a
03
Conditions
hepatitis C virus infectionchronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2010-022067-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022067-35.